Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK

PharmacoEconomics

Volumn 25, Issue 10, 2007, Pages 863-879

  Wolowacz, Sorrel E ^a,d   Roskell, Neil ^a   Kelly, Steven ^b   Maciver, Fiona M ^a   Brand, Chris S ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; COHORT ANALYSIS; EYE EXAMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA AGE RELATED DEGENERATION; SENSITIVITY ANALYSIS; SURVIVAL RATE; TREATMENT DURATION; UNITED KINGDOM; UNIVARIATE ANALYSIS; VISUAL ACUITY;

AGE FACTORS; AGED; AGED, 80 AND OVER; APTAMERS, NUCLEOTIDE; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; MACULAR DEGENERATION; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; QUALITY-ADJUSTED LIFE YEARS; REPRODUCIBILITY OF RESULTS; SEX FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 34748825182     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725100-00005     Document Type: Article

References (36)

1. Vingerling JR, Klaver CC, Hofman A, et al. Epidemiology of age-related maculopathy. Epidemiol Rev 1995; 17 (2): 347-59
2. Bressler SB, Bressler NM, Fine SL, et al. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 1982 Feb; 93 (2): 157-63
3. Brown GC, Sharma S, Brown MM, et al. Utility values and age related macular degeneration. AMA Arch Ophthalmol 2000; 118: 47-51
4. O'Neill C, Jamison J, McCulloch D, et al. Age related macular degeneration, cost-of illness issues. Drug Aging 2001; 18 (4): 233-41
5. Fitzgerald RG. Reactions to blindness: an exploratory study of adults with recent loss of sight. Arch Gen Psychiatry 1970; 22: 370-9
6. Evans RL. Loneliness, depression and social activity after determination of legal blindness. Psychol Rep 1983; 52: 603-8
7. Galaria II, Casten RJ, Rovner BW. Development of a shorter version of the Geriatric Depression Scale for visually impaired older patients. Int Psychogeriatr 2000; 12 (4): 435-43
8. Scott IU, Schein OD, Feuer WJ, et al. Emotional distress in patients with retinal disease. Am J Ophthalmol 2001; 131 (5): 584-9
9. Dutton GN. Age related macular degeneration: could we improve the services we offer? Br J Ophthalmol 2000; 84: 945-6
10. Berman K, Brodaty H. Psychosocial effects of age-related macular degeneration. Int Psychogeriatr 2006 Sep; 18 (3): 415-28
11. Javitt JC, Zhou Z, Willke RJ. Association between vision loss and higher medical care costs in Medicare beneficiaries: costs are greater for those with progressive vision loss. Ophthalmology 2007; 114 (2): 238-45
12. Meads C, Salas C, Roberts T, et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Tech Assess 2003; 7 (9): v-vi, 1-98
13. National Institute for Clinical Excellence. Guidance on the use of photodynamic therapy for age-related macular degeneration [technology appraisal 68, 2003 Sep] (online). Available from URL: http://www.nice.org.uk/page.aspx?.o= TA068guidance [Accessed 2006 Dec 1]
14. Pegaptanib summary of product characteristics. Sandwich, Kent: Pfizer Ltd, 2006
15. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16
16. Chakravarthy U, Adamis AP, Cunningham ET, et al. for the VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) clinical trial group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006 Sep; 113 (9): 1508-25
17. D'Amico DJ, Patel M, Adamis AP, et al. for the VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) clinical trial group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006 Jun; 113 (6): 992-1001
18. Government Actuary's Department. Population projections 2003 based [online]. Available from URL: http://www.gad.gov.uk/population [Accessed 2006 Dec 1]
19. Klein R, Klein BEK, Tomany SC, et al. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 2002; 109 (10): 1767-79
20. VISION trials patient-level data. Surrey: Pfizer Ltd, 2006 (Data on file)
21. NHS reference costs. London: Department of Health, 2004
22. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 2004 Sep; 88 (9): 1107-12
23. Mills E, Heels-Ansdell D, Kelly S, et al. Randomised trial of pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease modifying effects. J Clin Epidemiol 2007; 60 (5): 456-60
24. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal, 2004 Apr [online]. Available from URL: http://www.nice.org.uk/page.aspx?.o=201974 [Accessed 2006 Dec 1]
25. Office for National Statistics. Mortality statistics, general. Mortality rates, 2001. Deaths, 2001: rates per 1000 population by age-group and sex in the UK [from table 6] (series DH1, no. 34) 2001 [online]. Available from URL: http://www.statistics. gov.uk/statbase [Accessed 2006 Dec 1]
26. Office for National Statistics. Key health statistics from general practice, 1998. Table 5A7: prevalence of treated depression per 1000 patients, by age, sex and calendar year. 1994-98 [online]. Available from URL: http://www.statistics.gov.uk/StatBase/xsdataset.asp?.More=Y&vlnk= 2341&All=Y&B2.x=37&B2.y=12 [Accessed 2006 Dec 1]
27. Brennan J, Johamsen A, Butler J, et al. Place of residence and risk of fracture in older people: a population-based study of over 65-year-olds in Cardiff. Osteoporosis Int 2003; 14 (5): 515-9
28. Curtis L, Netten A. Unit costs of health and social care. Kent: University of Kent Personal Social Services Research Unit, 2005
29. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 50. London: BMA, RPS, 2005 Sep
30. Scottish Executive Health Department. NHS circular: PCS (DD)2005/5. 14 April 2005 [online]. Available from URL: http://www.sehd.scot.nhs.uk/pcs/ PCS2005(DD)05.pdf [Accessed 2007 Aug 17]
31. The Royal Commission on Long-Term Care. With respect to age: long-term care. Rights and responsibilities. London: The Stationery Office, 1999
32. Department of Work and Pensions, Housing Benefit and Council Tax Benefit. Annual summary statistics May 2003 [online]. Available from URL: http://www.dwp.gov.uk/asd1/hb_ctb/ht_ctb_annual_may03.asp [Accessed 2007 Aug 17]
33. Directgov. Central Office of Information [online]. Available from URL: http://www.direct.gov.uk [Accessed 2007 Aug 17]
34. Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003; 183: 514-9
35. Kaiser PK, and the Treatment of A-related macular degeneration with Photodynamic therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension. TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 2006 Sep; 244 (9): 1132-42
36. Scottish Medicines Consortium. Advice on pegaptanib (Macugen®), for use within NHS Scotland: pegaptanib 0.3mg solution for intravitreal injection [Macugen®] (290/06) [online]. Available from URL: http://www. scottishmedicines. org.uk/press/detail.asp?.id=1030 [Accessed 2006 Dec 1]